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OBJECTIVE — We investigated whether palmitoleate, which prevents insulin resistance in
mice, predicts insulin sensitivity in humans.
RESEARCH DESIGN AND METHODS — The fasting fatty acid pattern in the plasma
freefattyacid(FFA)fractionwasdeterminedin100subjectsatincreasedriskfortype2diabetes.
Insulin sensitivity was estimated during an oral glucose tolerance test (OGTT) at baseline and
after 9 months of lifestyle intervention and measured during the euglycemic-hyperinsulinemic
clamp (n  79).
RESULTS — Circulating palmitoleate (OGTT:F ratio  8.2, P  0.005; clamp:F ratio  7.8,
P  0.007) but not total FFAs (OGTT:F ratio  0.6, P  0.42; clamp:F ratio  0.7, P  0.40)
correlated positively with insulin sensitivity, independently of age, sex, and adiposity. High
baseline palmitoleate predicted a larger increase in insulin sensitivity. For 1-SD increase in
palmitoleate, the odds ratio for being in the highest versus the lowest tertile of adjusted change
in insulin sensitivity was 2.35 (95% CI 1.16–5.35).
CONCLUSIONS — Circulating palmitoleate strongly and independently predicts insulin
sensitivity,suggestingthatitplaysanimportantroleinthepathophysiologyofinsulinresistance
in humans.
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F
ree fatty acids (FFAs) are considered
to link obesity with insulin resis-
tance and type 2 diabetes (1,2).
Mechanisms include intracellular accu-
mulation of lipotoxic metabolites, such as
long-chainfattyacyl-CoA,ceramides,and
diacylglycerol, which interfere with insu-
lin signaling (2) and signaling via mem-
brane toll-like receptor 4 (3). However, a
signiﬁcantrelationshipbetweentotalFFA
levels and insulin resistance is not found
in all studies (4–6).
Most recently, the fatty acid palmi-
toleate (C16:1n7) was found to increase
insulin action in skeletal muscle and to
preventhepatosteatosisinmice,thusrep-
resenting a link between adipose tissue
and systemic metabolism (7). In the
present study, we investigated whether
palmitoleate may also be a determinant of
insulin sensitivity in humans.
RESEARCH DESIGN AND
METHODS— Data from 100 Cauca-
sians of the Tu ¨bingen Lifestyle Interven-
tion Program (8) were analyzed. Subjects
underwent measurements at baseline and
after 9 months of lifestyle intervention
(3 h of moderate sports per week, in-
take of calories from fat 30%, intake of
ﬁbers 15 g/1,000 kcal, intake of satu-
rated fat 10%). Informed written con-
sent was obtained from all participants,
and an ethics committee approved the
protocol. Body fat was measured by bio-
electricalimpedance,totalandvisceralfat
by magnetic resonance tomography, and
liver fat by
1H magnetic resonance spec-
troscopy (8). Insulin sensitivity was esti-
mated from a 75-g oral glucose tolerance
test(OGTT),asproposedbyMatsudaand
DeFronzo[10,000/(Insmean Glucmean 
Ins0   Gluc0)] and additionally measured
by the euglycemic clamp (8). The fatty
acids in the plasma FFA fraction were
measured as previously described (sup-
plemental Table 1 in the online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-0544/DC1) (9). For-
ward stepwise multivariate linear and
logistic regressions were performed.
RESULTS— Subject characteristics
are shown in supplemental Table 2. At
baseline, insulin sensitivity correlated in-
versely with body weight, BMI, waist cir-
cumference, total body fat, visceral fat,
andliverfat(allP0.0001).Totalfasting
FFA levels were lower in males (P 
0.0002). They were not associated with
ageorwithmeasuresofadiposity,liverfat
(all adjusted P  0.09), or insulin sensi-
tivity (OGTT:F ratio  0.6, P  0.42;
clamp:F ratio  0.7; P  0.40) indepen-
dently of sex, age, and body fat.
Circulating palmitoleate was lower in
males (4.38  0.19 vs. 5.03  0.14%,
P  0.007) and not associated with age,
or with measures of adiposity such as
body weight, BMI, waist circumference,
or total and visceral fat, adjusted for sex
and age (all P  0.23). Because palmi-
toleate in serum cholesteryl esters corre-
lated with high-sensitivity C-reactive
protein (hsCRP) levels (10), we also in-
vestigatedtherelationshipbetweencircu-
lating palmitoleate and adjusted hsCRP
levels. No signiﬁcant relationship was
found (P  0.44). A weak negative corre-
lation between palmitoleate and liver fat
was observed after adjustment for age,
sex, and body fat (F ratio  3.7; P 
0.057). In contrast, palmitoleate corre-
lated positively with insulin sensitivity
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ratio  7.8, Fig. 1B) independently of
sex, age, and body fat. Additional ad-
justment for visceral fat only moder-
ately affected these relationships (P 
0.017 and P  0.019).
Duringthe9monthsoflifestyleinter-
vention, insulin sensitivity and circulat-
ing palmitoleate increased (P  0.0001,
supplemental Tables 1 and 2). Change in
palmitoleate did not correlate with
changes in insulin sensitivity in all sub-
jects (n  95, OGTT P  0.67, and n 
38, clamp P  0.56). However, a positive
relationship was observed in subjects in
the upper tertile of insulin sensitivity
(OGTT) at baseline (r  0.41, P  0.03),
suggesting that in subjects starting with
low insulin sensitivity, the multiple ben-
eﬁts of lifestyle interaction such as reduc-
tion in adiposity or increased exercise
intensity have a stronger impact on insu-
lin sensitivity than change in palmitoleate
levels. In agreement with the analyses at
baseline, at the follow-up visit, palmi-
toleate levels also correlated positively
with adjusted insulin sensitivity (n  95,
OGTT:F ratio  5.0; P  0.029).
In forward stepwise linear regression
analyses including palmitoleate at base-
line, age, sex, insulin sensitivity at base-
line, and body fat at baseline and at
follow-up, high palmitoleate levels pre-
dictedalargerincreaseininsulinsensitiv-
ity (P  0.02, supplemental Table 3).
After dividing subjects into tertiles by the
observed change in insulin sensitivity, for
1-SD increase in circulating palmitoleate
at baseline, the odds ratio of subjects for
being in the highest versus the lowest ter-
tile of change in insulin sensitivity was
2.35 (95% CI 1.16–5.35).
CONCLUSIONS — We found that
circulating palmitoleate was a determi-
nant of insulin sensitivity both estimated
from the OGTT and measured by the
clamp. Furthermore, in subjects with
high palmitoleate at baseline, there was a
higher chance to observe an increase in
insulin sensitivity, independently of the
change in adiposity, compared with sub-
jects with low levels. These novel data
strongly support that palmitoleate may
also be involved in the regulation of insu-
lin sensitivity in humans.
In animals, palmitoleate infusion de-
creased expression of hepatic lipogenic
enzymes,thuspossiblyregulatingliverfat
(7), an important determinant of insulin
sensitivity in humans (11,12). We ob-
served a weak negative relationship be-
tween circulating palmitoleate and liver
fat,suggestingthat,inhumans,theeffects
of palmitoleate on the regulation of insu-
lin sensitivity may be more pronounced
than on hepatic steatosis.
Whatmechanismsareinvolvedinthe
determination of circulating palmi-
toleate? The lipid chaperons fatty acid–
binding protein (FABP)-4 and -5 were
found to suppress the biosynthesis of
palmitoleate (7). FABPs induce lipolysis
inadipocytesandinﬂammatorypathways
in macrophages, particularly in visceral
obesity (13). However, FABP expression
was not elevated in visceral obesity (14)
and, in the present study, palmitoleate
levels did not correlate with visceral fat
mass, suggesting that increase in this fat
compartment does not appreciably deter-
mine palmitoleate levels. Another regula-
tor of palmitoleate may be diet. However,
dietarylevelsofpalmitoleateareverylow.
Therefore, palmitoleate levels are most
probably not largely affected by the diet,
but mainly by de novo lipogenesis in ad-
iposetissue(7).Inaddition,stearoyl-CoA
desaturase-1, the key enzyme in the bio-
synthesis of palmitoleate from palmitate,
maydeterminepalmitoleatelevels.Thisis
supported by data showing that thiazo-
lidinedione treatment increased insulin
sensitivity, circulating palmitoleate, and
expression and activity of stearoyl-CoA
desaturase-1 in adipose tissue (15).
In conclusion, particularly the cross-
sectional analyses with measurements of
insulin sensitivity from both the OGTT
and the clamp suggest that palmitoleate
strongly and independently of adiposity
determines insulin sensitivity. Therefore,
circulating palmitoleate may also play an
important role in the pathophysiology of
insulin resistance in humans.
Figure 1—Cross-sectional relationships of circulating palmitoleate with insulin sensitivity esti-
mated from the OGTT (A) and measured by the clamp (B) at baseline. Insulin sensitivity was
adjusted for age, sex, and body fat in multivariate linear regression models (regression line and
95% CI). arb. units, arbitrary units.
Palmitoleate and insulin sensitivity
406 DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 care.diabetesjournals.orgAcknowledgments— The study was sup-
ported by grants from the Deutsche For-
schungsgemeinschaft (KFO 114 and a
Heisenberg-GranttoN.S.,STE1096/1–1)and
the European Community’s FP6 EUGENE2
(LSHM-CT-2004-512013).
No potential conﬂicts of interest relevant to
this article were reported.
The authors thank all participants for their
cooperation.
References
1. Rise ´rusU,WillettWC,HuFB.Dietaryfats
and prevention of type 2 diabetes. Prog
Lipid Res 2009;48:44–51
2. SavageDB,PetersenKF,ShulmanGI.Dis-
ordered lipid metabolism and the patho-
genesis of insulin resistance. Physiol Rev
2007;87:507–520
3. Shi H, Kokoeva MV, Inouye K, Tzameli I,
Yin H, Flier JS. TLR4 links innate immu-
nity and fatty acid-induced insulin resis-
tance. J Clin Invest 2006;116:3015–3025
4. Perseghin G, Scifo P, De Cobelli F, Pa-
gliato E, Battezzati A, Arcelloni C, Van-
zulli A, Testolin G, Pozza G, Del Maschio
A, Luzi L. Intramyocellular triglyceride
content is a determinant of in vivo insulin
resistance in humans: a 1H-13C nuclear
magnetic resonance spectroscopy assess-
ment in offspring of type 2 diabetic par-
ents. Diabetes 1999;48:1600–1606
5. StefanN,KantartzisK,MachannJ,Schick
F, Thamer C, Rittig K, Balletshofer B,
MachicaoF,FritscheA,Ha ¨ringHU.Iden-
tiﬁcationandcharacterizationofmetabol-
ically benign obesity in humans. Arch
Intern Med 2008;168:1609–1616
6. RodenM.Howfreefattyacidsinhibitglu-
coseutilizationinhumanskeletalmuscle.
News Physiol Sci 2004;19:92–96
7. Cao H, Gerhold K, Mayers JR, Wiest MM,
Watkins SM, Hotamisligil GS. Identiﬁca-
tionofalipokine,alipidhormonelinking
adipose tissue to systemic metabolism.
Cell 2008;134:933–944
8. Stefan N, Hennige AM, Staiger H,
Machann J, Schick F, Kro ¨ber SM, Machi-
cao F, Fritsche A, Ha ¨ring HU. Alpha2-
Heremans-Schmid glycoprotein/fetuin-A
is associated with insulin resistance and
fat accumulation in the liver in humans.
Diabetes Care 2006;29:853–857
9. StefanN,WahlHG,FritscheA,HaringH,
Stumvoll M. Effect of the pattern of ele-
vated free fatty acids on insulin sensitivity
and insulin secretion in healthy humans.
Horm Metab Res 2001;33:432–438
10. Petersson H, Basu S, Cederholm T,
Rise ´rus U. Serum fatty acid composition
and indices of stearoyl-CoA desaturase
activity are associated with systemic in-
ﬂammation:longitudinalanalysesinmid-
dle-aged men. Br J Nutr 2008;99:1186–
1189
11. Stefan N, Kantartzis K, Ha ¨ring HU.
Causes and metabolic consequences of
fatty liver. Endocr Rev 2008;29:939–960
12. Roden M. Mechanisms of disease: hepatic
steatosis in type 2 diabetes–pathogenesis
and clinical relevance. Nat Clin Pract En-
docrinol Metab 2006;2:335–348
13. FuruhashiM,HotamisligilGS.Fattyacid-
binding proteins: role in metabolic dis-
eases and potential as drug targets. Nat
Rev Drug Discov 2008;7:489–503
14. Fisher RM, Eriksson P, Hoffstedt J, Hota-
misligilGS,Tho ¨rneA,Ryde ´nM,Hamsten
A, Arner P. Fatty acid binding protein ex-
pressionindifferentadiposetissuedepots
fromleanandobeseindividuals.Diabeto-
logia 2001;44:1268–1273
15. Rise ´rus U, Tan GD, Fielding BA, Neville
MJ, Currie J, Savage DB, Chatterjee VK,
Frayn KN, O’Rahilly S, Karpe F. Rosigli-
tazone increases indexes of stearoyl-
CoA desaturase activity in humans: link
to insulin sensitization and the role of
dominant-negative mutation in peroxi-
some proliferator-activated receptor-
gamma. Diabetes 2005;54:1379–1384
Stefan and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 407